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REPLY
We thank Drs. Bahl and Chongtham for their interest in our study
on the effects of atorvastatin on systolic function and markers of
inflammation in patients with nonischemic heart failure (HF) (1).
We agree with them that nonischemic HF represents a heteroge-
neous condition with various etiologies. The authors correctly
point out that duration of illness is an important determinant in
response to therapy in patients with nonischemic HF. Patients
with newly diagnosed nonischemic HF, for example, may have
myocarditis with transient left ventricular (LV) systolic function
followed by a spontaneous improvement in ventricular function,
regardless of medical therapy.
We disagree, however, that patients in this trial should have
been randomized according to duration of illness. The inclusion
criteria for this study required that patients on stable HF medica-
tions for at least three months before study entry, effectively
excluding patients with more transient forms of nonischemic HF
that may be likely to resolve spontaneously. Moreover, we believe
that other factors play a much more important role in determining
response to therapy and long-term prognosis in these patients. For
example, Felker et al. (2) followed 1,230 patients with nonischemic
HF for an average of 4.4 years and found that older age, male
gender, and etiology of HF were associated with increased mor-
tality. Other teams have demonstrated that prognosis in this group
of patients is primarily determined by age, LV ejection fraction,
and symptomatic HF (3,4).
In conclusion, our study demonstrated that therapy with ator-
vastatin improved LV systolic function and markers of inflamma-
tion in patients with chronic forms of nonischemic HF—results
that we believe were relatively unbiased by duration of illness.
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Beta-Blockers and Exercise
In a recent issue of JACC, Kokkinos et al. (1), after evaluating the
role of beta-blockers at mitigating exercise-induced blood pres-
sure (BP) rise in hypertensive men, concluded that “for patients
engaging in vigorous activities such as snow-shoveling, basketball,
tennis, racquetball, and so on, beta-blockade–based therapy can
protect against excessive and repetitive elevations in BP which may
occur during such activities.”
Earlier studies have shown that beta-blockers bring about a clear
reduction in exercise endurance in young healthy subjects (2,3) and
trained sportsmen (4,5). Similarly, in patients with hypertension
who are on beta-blockers, the reduction in exercise tolerance in
part could be attributable to be secondary to these drugs (6). In the
study by Kokkinos et al. (1), both the exercise duration and the
total metabolic equivalents achieved were significantly lower in the
group on beta-blockers compared to other medications. In the
ASCOT–BPLA (Anglo-Scandinavian Cardiac Outcome Trial–
Blood Pressure Lowering Arm) study of 19,257 patients with
hypertension and at least three other coronary risk factors but no
coronary artery disease, atenolol-based treatment resulted in a 14%
higher risk of coronary events and a 23% increase in stroke rate
compared to amlodipine-based regimen (7). In a recent meta-
analysis of 134,000 patients on antihypertensive therapy, beta-
blocker treatment was associated with a 16% higher incidence of
stroke compared to other antihypertensive treatments (8). Of note,
beta-blockers have recently been shown to differ in their effect on
central aortic BP compared to peripheral brachial pressure. The
Conduit Artery Functional Endpoint (CAFÉ trial) and other
studies have documented that beta-blockers have a lesser effect on
central systolic pressure than do angiotensin-converting enzyme
(ACE) inhibitors, diuretics, and calcium antagonists (9–11). In
fact, results of the CAFÉ (12) study show that a calcium
antagonist–based treatment is much more effective at reducing
central aortic BP than is a conventional atenolol-based (beta-
blocker) regimen. Importantly, the study also suggests that the
central aortic BP may be more predictive of cardiovascular events,
such as stroke and myocardial infarction, than traditional periph-
eral (brachial) BP measurements (12).
We believe, therefore, that a conclusion, such as the above,
based on peripheral BP measurements may be inappropriate. For
hypertensive patients engaging in “vigorous activities,” we do need
a medication that curtails their (central) BP rise but not one that
curtails their activity.
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